Why the study?
Does a modified infusion of rtPA 100 mg over 4 hours safely and effectively treat high-risk pulmonary thromboembolism in a patient with high bleeding risk?
Does a modified infusion of rtPA 100 mg over 4 hours safely and effectively treat high-risk pulmonary thromboembolism in a patient with high bleeding risk?
A modified slower infusion of 100 mg rtPA over 4 hours may be an effective and safer thrombolysis regimen for acute high-risk pulmonary thromboembolism in patients with high bleeding risk.
May support extended rtPA infusion in high-bleeding-risk PE; leaves open confirmation in prospective trials.
High-risk pulmonary thromboembolism (PTE) is a form of venous thromboembolism that refers to severe obstruction of pulmonary vessels, which causes right ventricular failure and hemodynamic instability. High-risk PTE has a high mortality rate unless immediate reperfusion treatment is done. Systemic thrombolysis is recommended for patients with high-risk PTE. The approved regimen for high-risk PTE is the accelerated intravenous administration of recombinant tissue-type plasminogen activator (rtPA) 100 mg over 2 hours. Herein, we present a case of high-risk PTE in a 74-year-old woman with a high risk of bleeding due to a recent pelvic fracture and head trauma who was successfully treated with a slower infusion of 100 mg rtPA over 4 hours. The modified infusion rate of 100 mg rtPA over 4 hours is an effective regimen for thrombolysis in acute high-risk PTE. It might have a lower risk of bleeding complications, which makes it a good option for patients with high bleeding risk.
No takes yet. Share an insight, caveat, or question.
Hasin et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: